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Background: Depression is common in schizophrenia. Whereas the improvement of mood and self-esteem represents a subjective treatment 
priority for many patients, depression is rarely a primary target for clinical intervention.The present trial examined whether an online intervention 
for depression can ameliorate depressive symptoms in schizophrenia. Methods: A total of 58 individuals with schizophrenia were invited to 
participate in an online survey which encompassed the Center for Epidemiologic Studies-Depression Scale (CES-D, primary outcome), the 
Patient-Health-Questionnaire-9 (PHQ-9) and the Paranoia Checklist. Subsequently, telephone interviews were conducted to verify diagnostic 
status and assess symptoms (Positive and Negative Syndrome Scale, PANSS). Participantswere randomized either to the experimental condition 
(online depression intervention) or to a waitlist control condition. Three months after inclusion, a reassessment was carried out (self-report and 
telephone interviewblind for group condition). The trial was registered (registration: DRKS00007888). 
Results: Participants in the treatment group showed a significant decline of depressive symptoms at a mediumto- large effect size, as 
assessedwith the CES-D and the PANSS depression item, in comparison to thewaitlist control group (completer (CC) and intention-to-treat 
analyses (ITT)). For the PHQ-9 (CC and ITT) and the PANSS distress subscale (CC only) significance was bordered at a medium effect size. 
Completion at the post-assessment after three months was 84%. 
Discussion: Depression in schizophrenia is both underdiagnosed and undertreated. To reduce the large treatment gap in the disorder, low 
threshold strategies are urgently needed. Online treatment and bibliotherapy may represent valuable tools to address patients' needs beyond the 
treatment of the core positive syndrome. 
 
1. Introduction 
1.1. Depression in schizophrenia 
Delusions and hallucinations (i.e., positive symptoms) are the defining features of psychosis and until recently represented the 
conventional target for the treatment of schizophrenia (Suzuki, 2011). In contrast, depressive symptoms in this disorder 
received comparatively little attention, presumably owing to historical and diagnostic reasons. Since Kraepelin (1899) who 
separated schizophrenia (then called dementia praecox) from affective disorders and more recently Schneider (1959) who 
confined the core of schizophrenia to positive features, depression is often regarded a negligible and secondary symptomatic 
feature of psychosis. Moreover, some phenomena that would be ounted as depressive symptoms in other disorders are labeled 
as negative symptoms in schizophrenia (e.g., social withdrawal) or even receive distinct diagnostic terms once a diagnosis of 
schizophrenia has been determined (Burckhardt, 2012; Kuck et al., 1992). For example, a mental state dominated by affective 
numbness is usually termed melancholia in depression but anhedonia in psychosis. Similarly, lack of drive (depression) is 
commonly relabeled as avolition in schizophrenia and again counted as a negative symptom. This, along with the longstanding 
preoccupation that psychosis is not amenable to understanding (Jaspers, 1973; Walker, 1991), may have contributed to the 
relative neglect of treatment of depressive symptoms in psychosis in the past and to the poor transfer of available psychological 
treatment options against depression in patients with psychosis. 
 
1.2. Reasons why depression is an important treatment target in schizophrenia 
A number of reasons existwhy depressive symptoms deserve greater attention in the treatment of psychosis. First, 
beginningwith Kasanin 
(1933), who coined the term schizoaffective disorder, clinicians increasingly acknowledge that affective symptoms coexist with 
psychosis.  
A review estimated that at least 50% of patients suffer from comorbid depression (Buckley et al., 2009), and many patients 
show single  depressive symptoms such as low self-esteem (Freeman et al., 1998; Kesting and Lincoln, 2013; Moritz et al., 
2010). Second, suicidality, a grave and life-threatening manifestation of depression, is frequent in psychosis and approximately 
5% of patients commit suicide (Hor and Taylor, 2010).While some suicides are due to the influence of acoustic hallucinations, 
depression represents the best predictor for suicidality or selfharm behaviors in patients with schizophrenia (Fusar-Poli et al., 
2014). Third, the implicit prevailing treatment paradigmposits that improving positive symptoms and insight will raise quality of 
life and reduce depression. Research suggests, however, that enhancement of insight can even paradoxically aggravate 
affective problems (Karow et al., 2008; Lincoln et al., 2007). Moreover, depression is not just a secondary consequence of 
having a severe mental disorder, it is also a frequent premorbid precursor of psychosis (Fusar-Poli et al., 2014). Fourth, 
depressive symptoms are often formulated by patients as their preferred target of treatment (Byrne et al., 2010; Hafner et al., 
2013; Sterk et al., 2013; Moritz et al., in press-b).  
 
1.3. Poor efficacy of available treatment 
Notwithstanding the need to address depression in the therapy of psychosis as well as guidelines fostering psychotherapy in 
psychosis, 
many patients are still deprived of psychotherapy in general (Bechdolf and Klingberg, 2014; Shafran et al., 2009). If 
psychotherapy is sought at all, it often targets positive symptoms. Both pharmacological and psychological treatment 
approaches for psychosis are only partially effective in reducing depression. Antipsychotics yield a small effect size for the 
improvement of depressive symptoms in schizophrenia (Leucht et al., 2009). In fact, antipsychotic medication may even induce 
pharmacological depression (Naber and Karow, 2001). Augmentation with antidepressants has been shown ineffective for the 
treatment of depressive symptoms according to two meta-analyses (Kishi et al., 2013; Kishi and Iwata, 2014), underlining the 
need for non-pharmacological treatment options for depression in psychosis patients. Cognitivebehavioral therapy (CBT) yields 
a small to medium effect size (0.36) for the improvement of mood (Wykes et al., 2008). 
 
1.4. The present study 
The present study explored whether a generic online intervention for depression administered in a non-clinical setting can 
reduce depressive 
symptoms in patients with psychosis. We used a program called HelpID (developed by the novego AG) which is based on the 
CBT 
theoretical framework. Meta-analyses show that online interventions for depression exert a small-to-medium effect size in 
patients with depression when administered unguided (Cuijpers et al., 2011; Richards and Richardson, 2012, Johansson and 
Andersson, 2012). 
Whether these effects also hold true for patients with comorbid depressive symptoms alongside other primary disorders, like 
obsessive-compulsive disorder, borderline personality disorder and schizophrenia, awaits to be established. While we 
hypothesize that 
HelpID will reduce depressive symptoms in psychosis, we were unable to make predictions with respect to the magnitude of the 
effect. Although self-help and online interventions have proven feasible in psychosis (Alvarez-Jimenez et al., 2014), a limiting 
factor could be that 
the online intervention under investigation is not adapted to the specific problems (e.g., stigma and self-stigma) and deficits 
(e.g., cognitive dysfunctions which may compromise translation of lessons/learning aims into everyday life) of psychotic 
patients. However, as patients with psychosis often do not receive specific treatment for depression, the potential of the 
program may be higher than in conventional (depression) populations who are usually not naïve about the contents of such 
programs. In linewith this, themagnitude of the effect of online interventions for depressionwasmoderate for a group of 
neurological patients in two recent studies of whom most had never received specific treatment for depression before (Fischer 
et al., 2015; Schröder et al., 2014). Based on the assumption that depressive symptoms and depression-related cognitions 
(e.g., worry thinking style, negative beliefs about the self, interpersonal sensitivity, sleep disturbance) play a causal role for the 
emergence of positive symptoms (Garety et al., 2001; Freeman and Garety, 2014; Lincoln et al., 2014),we also expected the 
treatment to impact on positive symptoms. 
 
2. Method 
2.1. Participants 
Participants were primarily recruited via a database of former patients fromthe Department of Psychiatry and Psychotherapy at 
the University Medical Center Hamburg-Eppendorf (Germany, UKE). All former patients had previously given written informed 
consent to be 
re-contacted for future studies. While for most individuals a diagnosis of schizophrenia had been established on prior 
occasions, we additionally administered a diagnostic telephone interviewas a precondition for participation. We also contacted 
high-quality Internet forums (e.g. moderated, conveying evidence-based information) devoted to schizophrenia as an additional 
source to recruit study participants. The following inclusion criteria applied: age between 18 and 65 years, willingness to 
participate in two anonymous (Internet-based) surveys aswell as diagnostic telephone interviews that were scheduled 
threemonths apart, and a diagnosis of schizophrenia (as verified by telephone interview). Moreover, participants had to 
experience present subjective depressive symptoms and a willingness to undergo treatment for these symptoms (no formal cut-
off was set). While presence of depressive symptoms was an explicit inclusion criterion, a diagnosis of major depression or 
dysthymic disorder was not. Severe suicidality led to exclusion. In these cases, participants were informed about help lines and 
treatment options. The trial was set up as an add-on intervention to care-as-usual: Participants were informed that the trial 
would not interfere with current treatments. For example, individuals were allowed to continue to take medication or see a 
physician.Interested individuals were directed to the baseline survey via a weblink. The survey was set up using questback®, a 
software allowing to create online surveys. The study was anonymous (no name or postal address was requested; we did no 
store IP addresses were stored). Participants were informed that they would either immediately receive an online code allowing 
a free 3-month access to HelpID or would be allocated to a waitlist control condition. The latter group was promised full access 
to the program subsequent to the post-assessment (online survey and interview). Group allocation was carried out in random 
fashion subsequent to baseline assessment (i.e. following the interview) using an automated randomization plan with no 
stratification. The trial was registered at the Internet Portal of the German Clinical Trials Register (DRKS; DRKS00007888). The 
DRKSwas approved for the primary register in theWHO network and thusmeets the requirements of the International 
Committee of Medical Journal Editors (ICMJE). 
 
2.2. Procedure 
On the first page of the baseline survey, the rationale of the study as well as exclusion criteria were summarized. All 
participants provided 
electronic informed consent. Multiple log-ins via the same computer were prevented by means of “cookies”. The survey 
consisted of the following parts: demographic section (e.g., gender, age), medical history (e.g., psychiatric diagnoses), 
assessment of psychopathology (see 
questionnaires section below), request for an email address (to match baseline and post-survey data), telephone number and 
contact information (e.g., preferred times for the interview) and whether prior responses had been correct. Following completion 
of the baseline 
assessment, interviewers tried to reach individuals at their preferred times to carry out the telephone interview (the 
assessments are described below). Telephone interviews were conducted blinded for  group allocation and patients were 
explicitly reminded at the reassessment not to disclose which condition they had been allocated to. Following the blinded 
interview (see below) eligible participants 
were randomized (see above). Participantswere emailed by a researcher (JS) not involved in the interviews and informed 
aboutwhether they were allocated to the intervention group (a voucher providing access to the program was included along with 
further instructions) or the waitlist control group. Three months after the baseline interview, participants were contacted via 
email for participation in the post-survey. Up to two reminders were dispatched if participants failed to complete the 
postassessment. For the post-survey, individuals were requested to first enter their email address to allow matching of baseline 
and post data. The postassessment consisted of the following parts: introduction, questionnaire on psychopathology (see 
below) and evaluation of the online intervention (if participants stated that they had logged in to the systemat least once). At the 
end, participants were asked whether they had made truthful responses and were given the opportunity to leave comments 
(e.g., if they experienced technical problems). They were then asked for their telephone number again and for their preferred 
times for the final interview. Following the final blinded interview, participants in the waitlist control group received an email 
containing a code giving full access to the program. All participants received a relaxation manual with audio files as an 
additional incentive. 
 
2.3. HelpID 
The Internet intervention Help ID (developed by novego AG, Seevetal, Germany) involves 12 weekly scheduled modules, which 
are 
derived from a pool of 17 modules (see below; 7 of these modules are mandatory). The individual set is composed according to 
the replies 
from a pre-assessment containing 60 questions which is performed prior to starting the program. Thus, every user receives a 
program tailored to their individual needs. Each module requires 45 to 60 min to complete and includes 14–19 pages of text. A 
video moderation leads through the program, which also includes interactive exercises and practice sheets, illustrations, 
photographs, animations and audios. For standard use of the program, motivational SMS (optional), email reminders and 
personal feedback on individual questions in a protected area are provided by the psychological team. For the present study 
however, no personal feedbackwas given aswewanted to evaluate the efficacy of a fully unguided treatment program. The 
program is based on a combination of therapeutic methods derived from CBT, acceptance and commitment therapy (ACT) as 
well as systemic counseling and therapy also including relaxation audio files and music therapy, provided using an 
individualized algorithm considering gender-specific and symptom-related aspects, somatic variables (such as chronic back 
pain or cardiac arrhythmia) and potentially also postpartum depression. Additional modules on, for example, heart problems 
and post-partumdepressionwere presented if corresponding cue questions (here, on diagnosed heart deficits or the birth of a 
child 
in the last year) were affirmed. The algorithmalso took into account responses on the PHQ. Essential contents and goals of the 
program are to convey an understanding of depression by means of psychoeducation, the development of alternative 
viewpoints fostering activation in everyday life, strengthening social relationships as well as attention and relapse prevention 
exercises. The titles of the 17 modules are as follows (modules that are underlined are mandatory and administered to every 
individual): the way out of depression • getting started if you  have the “blues” • depression• pleasant things in everyday life • 
learning to reward yourself • how to break thought spirals • together against depression • recognizing yourself • relaxation 
against depression • attention – made easy • learning to let go • doingmyself a favor • sun against murky thoughts • listen to 
your body • preventing relapse • therapeutic support • my heart and I. While seven of the modules were presented to each 
individual, five additional moduleswere selected according to individual responses to cue questions. 
 
2.4. Questionnaires (online assessment) 
Participants were required to complete three questionnaires. The survey proceeded only if all items had been responded to. 
 
2.4.1. Primary outcome 
The Center for Epidemiologic Studies-Depression Scale (CES-D) (Hautzinger and Brähler, 1993; Radloff, 1977) is a 20 
itemquestionnaire covering depressive symptoms. In keeping with efforts to give patients' preferences and assessment greater 
consideration (Karamatskos et al., 2012), this scale represented the primary outcome of the study. The CES-D has both a good 
internal consistency and test-retest reliability (r =0.81). Its validity has been confirmed against the Beck Depression Inventory 
(Beck and Steer, 1993). Items from the CES-D were mixed with those with the Paranoia Checklist.  
 
2.4.2. Secondary outcomes 
The Patient Health Questionnaire (PHQ-9; Kroenke et al., 2001) was assessed as an additional index of depression. The PHQ-
9 is a selfreport instrument derived from the Primary Care Evaluation of Mental Disorders (PRIME-MD). Its nine items tap into 
the nine diagnostic criteria in the DSM-IV. Its psychometric properties can be judged as good with a sensitivity of 0.80 and a 
specificity of 0.92 (Gilbody et al., 2007). The Paranoia Checklist (Freeman et al., 2005) consists of 18 items tapping into 
subclinical as well as clinical signs of paranoid beliefs and suspiciousness. The psychometric properties are good (Freeman et 
al., 2005; Lincoln et al., 2010). The test-retest reliability of the online version is excellent (Moritz et al., in press-a; Moritz et al., 
2014) and the scale shows good internal consistency and convergent validity (Lincoln et al., 2010). In our adaption of the scale, 
patients were required to rate the current symptom severity on a five-point Likert scale ranging from 1 (not at all) to 5 
(extremely). 
 
2.5. Psychopathological interview 
A diagnosis of schizophrenia or schizoaffective disorderwas verified via telephone using the Mini-International Neuropsychiatric 
Interview 
(M.I.N.I.; Sheehan et al., 1998). Interviewers were blind to group status (intervention or control group). The M.I.N.I. has been 
successfully validated against other diagnostic tools (Sheehan et al., 1998). Symptomseverity was measured with the Positive 
and Negative Syndrome Scale (PANSS; Kay et al., 1989), which is considered the gold standard for the psychometric 
assessment of schizophrenia (Suzuki, 2011). The PANSS has good psychometric properties and is sensitive to change (Kay et 
al., 1989; Peralta and Cuesta, 1994; Santor et al., 2007). In 
order to avoid repetition of questions, both ratings were synthesized into one interview and not administered successively. 
Ratings followed semi-structured interview protocols. Before the trial, a rater training was held using several video 
demonstrations. In addition, the first interview was monitored by an experienced rater (JS). The same rater administered the 
interview for each individual patient to avoid rating biases. For the PANSS, we adopted a five-factor algorithm suggesting 
 
the following subscales: 
positive symptoms, negative symptoms, disorganization, excitement, and emotional distress (van der Gaag et al., 2006). The 
general item 6 (depression) served as an index for clinician-rated depression. However, as negative symptoms cannot be 
reliably assessed over the telephone, we did not calculate the PANSS negative subscale. 
 
3. Results 
A total of 174 participants accessed the first page of the survey; 105 participants provided their electronic informed consent. 
Seventy-nine 
participants completed the entire baseline survey. Of these, 21were excluded for the reasons provided in the CONSORT chart 
(Fig. 1). Themain reason was that patients could not be reached via telephone (n = 11) because they either did not answer the 
phone (n = 6), did not leave a telephone number at all (n = 2), or left a wrong telephone number (n=3). Thus, 58 participants 
fulfilling inclusion criteria were randomized to the two conditions.  
 
3.1. Baseline characteristics & attrition 
The baseline characteristics of the sample are provided in Table 1. Except for a marginal difference on age, the groups did not 
differ on any baseline parameter. Depressive symptoms, as assessed with the PHQ-9, were moderate to severe. The PANSS 
total score signaled mild/ 
sub-acute symptomatology for most patients. The majority of participants were on medication (HelpID: 45.5% medication only, 
9% psychotherapy only, 45.5% both; waitlist control: 61.1% medication only, 0% psychotherapy only, 38.9% both, χ2(1) = 2.20, 
p = 0.33). As shown in Table 1,most individuals fulfilled diagnostic criteria for current (comorbid) depression. The rest either 
were diagnosed with depressive episodes in the past, dysthymia or did not fulfill formal criteria for depression. After three 
months, 84% of the sample (n = 49, HelpID: n = 25, waitlist: n = 24) were reached for the post-assessment (self-report and 
expert rating with the PANSS). Treatment status or concurrent treatment (e.g., lowered or enhanced dosage) did not change 
substantially between groups across time (p N 0.1). 
 
3.2. Statistical analyses 
In line with recommendations in the literature, we performed an ANCOVA with the pre-post difference score as the dependent 
variable 
and the respective baseline score as the covariate. This type of analysis  accounts for regression to the mean and raises power 
of the analyses (Borm et al., 2007; Kenward and Roger, 1997). 
 
 
 
3.3. Primary outcome (complete cases) 
For the primary outcome (CES-D) a significant difference emerged, F(1,46) = 9.84, p = 0.003, ηpartial2 = 0.176 with a large effect 
size in 
favor of the intervention group relative to the waitlist group (see Fig. 2). Paired t-tests showed that symptoms decreased 
significantly in 
the treatment (p=0.002) but not in the control condition (p=0.822).  
 3.4. Secondary outcomes (complete cases) 
For the PHQ-9 a trend in favor of the treatment group emerged at a medium effect size: ANCOVA: F(1,46)=3.71, p=0.06, ηpartial 
2 =0.075(see Fig. 3). Paired t-tests showed that symptom decrease bordered on significance in the treatment (p = 0.052) but 
not in control group (p=0.788). As the PHQ-9 is a very short scale tapping into a heterogeneous set of symptoms, we 
conducted exploratory item-wise comparisonswhich revealed three differences in favor of the intervention group relative to the 
waitlist control group, particularly for self-esteem: PHQ item 6 (low self-esteem; p = 0.003, ηpartial 2 = 0.175), PHQ item 3 (sleep; 
p = 0.052, ηpartial 2 = 0.080) and PHQ item 7 (poor attention; p=0.064, ηpartial 2 =0.073). No group differences emerged on the 
Paranoia Checklist across time, F(1,46)=0.13, p=0.91, ηpartial 2 b 0.001 (see Fig. 4). The PANSS depression item (general item 
6) score decreased more strongly in the intervention group than in the waitlist control group at a medium-to-large effect size, 
F(1,45) = 5.07, p = 0.029, ηpartial 2 = 0.101 (see Fig. 5). We then looked at the PANSS syndrome scales, whereby a marginally 
significant effect emerged for the PANSS distress subscale at amediumeffect size, p=0.054, ηpartial 
2 =0.078. For all other PANSS syndrome scores, the effects were non-significant (positive: p= 0.986, disorganization: p=0.172, 
excitement: p=0.245). Exploratory item-wise analyses revealed a significant difference in favor of HelpID for blunted 
affect,which howeverwould have notwithstood correction for multiple testing (PANSS item N1), F(1,46) = 5.37, p = 0.025, ηpartial 
2 = 0.104.  
 
 
 
 
3.5. Intention-to-treat analyses 
For intention-to-treat analyses considering all randomized patients, missing outcome data were imputed from information on the 
psychopathological and three demographic (age, gender, school education) indexes by the expectation-maximization (EM) 
algorithm, trimmed to fall between the minimumand maximumof possible values. This produced largely similar findings for all 
variables: CES-Q (F(1,55) = 12.023, p = 0.001, ηpartial 2 = 0.179), PANSS depression (F(1,55) = 4.356, p = 0.042, ηpartial 2 = 
0.073), PHQ-9 (F(1,55) = 2.901, p = 0.094, ηpartial 2 = 0.05), PANSS positive (F(1,55) = 0.161, p = 0.690, ηpartial 2 = 0.003), 
PANSS disorganization (F(1,55) = 2.540, p = 0.117, ηpartial 2 = 0.044), PANSS excitement (F(1,55) = 3.218, p = 0.078, ηpartial 2 = 
0.055), PANSS distress (F(1,55) = 2.591, p = 0.113, ηpartial 
2 = 0.045), Paranoia Checklist (F(1,55)= 0.061, p = 0.806, ηpartial 2 =0.001). 
 
3.6. Subjective appraisal 
All individuals in the HelpID condition logged in to the program at least once. Three individuals acknowledged that they did not 
perform 
the exercises. Table 2 shows that more than almost two thirds treatment group would recommend the training to a friend, would 
use the 
program again, found the quality of the program good and regarded the program as being helpful in dealing with problems. 
Endorsement 
was lower for the following domains: individual help, useful for one's needs, satisfied with the degree of the help received by the 
program and satisfaction overall. 
 
 
3.7. Adherence 
A total of 16% of the sample used the program daily or almost daily, 28% used it once each week and 12% every two weeks. 
24% used it once throughout the treatment period; 12% of the participants entered the programbut did not complete 
anymodule. On average, patients logged in 28.71 times (SD=46.67; range: 2–232).  
 
3.8. Test-retest reliability 
The three-month reliability was r = 0.62 for the PANSS total score (corrected for the negative items), r = 0.79 for the CES-Q, 
r=0.70 for 
the Paranoia Checklist and r = 0.62 for the PHQ-9. 
 
4. Discussion 
Our study examined whether a generic and unguided online selfhelp intervention for depression, leads to an improvement of 
depressive 
symptoms in individualswith schizophrenia. Treatment of depression is of high importance in view of its prevalence in 
schizophrenia and because regulation of emotional problems represents a high treatment priority in patients (Byrne et al., 2010; 
Sterk et al., 2013; Moritz et al., in press-b). We combined the advantages of online research (e.g., economic implementation, 
facilitated access to patients of whom 
many would not have participated in an institutional treatment context) with that of a randomized-controlled clinical trial (RCT; 
diagnostic 
interview, external assessment with a gold-standard instrument, PANSS). We were able to recruit 58 individuals with a valid 
diagnosis 
of schizophrenia and reached 84% of the participants after threemonths. The majority of participants liked the program, found it 
helpful, would use it again and would recommend it to others, notwithstanding that the program did not address individual 
problems of patients with schizophrenia. This retrospective assessment was also mirrored by the main outcome: In line with our 
hypothesis, we observed a significant and large decline of depressive symptoms in the HelpID group relative to the waitlist 
control as assessed with the CES-D. While the results pointed into a similar direction (medium effect size) for the PHQ-9, the 
group differences only reached trend level for this scale. An exploratory post-hoc assessment of individual PHQ-9 items 
revealed group differences for self-esteem (PHQ item 6). For the PANSS depression item we found a significant difference with 
a medium-to-large effect size in favor of HelpID. The distress subscale, which also captures anxiety, revealed a trend in favor of 
HelpID. No significant differences were measured for the PANSS positive syndrome or Paranoia Checklist. Thus, it seems that 
reducing depression does not suffice to reduce positive symptoms as assessed by this scale. However, a longer follow-up 
investigation is currently planned to explorewhether a reduction of depressive symptomis followed by improvement on positive 
symptomsat a later time-point (“sleeper effect”) as predicted by recent theoretical models (Freeman and Garety, 2014). Before 
drawing conclusions and suggesting ideas for future research, several limitations should be brought to the readers' attention. 
First, the sample sizewas rather small precluding elucidation of factors moderating outcome. Second, further follow-up studies 
are needed, ideally ones that include an active control condition to detectwhether improvement is sustained over time. Third, 
unlike conventional randomized controlled trials (RCTs), it is impossible to determine the screening-toinclusion ratio and to 
detect howthose participating in the trial differed from those who decided against it. Thus, despite encouraging evidence for the 
feasibility and efficacy of the approach its effectiveness needs to be replicated in a routine setting. Finally, while assessment 
with the PANSS is feasible for positive and depressive symptoms via the telephone, negative symptoms are hard to verify 
without face-to-face contact so that we could not compute scores for the PANSS negative subscale. To conclude, the study 
showed that an online intervention can improve depressive symptoms in individuals with psychosis. The magnitude of the effect 
was larger than was expected from prior studies in patients with primary depression (Spek et al., 2007). We speculate that this 
is due to the naivety of the recruited individuals concerning the contents of depression treatment which permitted its full 
potential to unfold. In contrast, many depressed patients undergoing online interventions for depression are usually familiar with 
standard face-to-face therapy thereby limiting surplus effects. Of note, the effect sizes were larger than those found for 
conventional treatment options for depression in psychosis such as antipsychotic (small effect) and antidepressant agents 
(negligible effect) and CBT (small-to-medium effect). We think that the larger “dosage” of the program (e.g., weekly sessions 
over 12 weeks) might have augmented the effect. Future studies should investigate whether guided interventions as well as 
incorporating elements addressing the needs and special problems of schizophrenia patients (e.g., stigma, socialwithdrawal, 
distrust, voice-hearing) can enhance the observed effects and generalize to psychotic symptoms. 
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